normal 0 false false false en-us x-none ar-sa background: from the thousands of years, metal compounds have been used in medicine for treatment of various diseases including various types of cancers. ruthenium was seen as a promising metal due to its similar kinetics to platinum and its lower toxicity. therefore, we aimed to evaluate the newer mononuclear ruthenium (ii) compounds for antinocice...

The chemistry of metal cyclopropenyl complexes derived from deprotonation of cationic ruthenium vinylidene complexes is reviewed. Such a metal coordinated cyclopropenyl ligand can be used for the preparation of heterocyclic compounds. The chemical reactivity of cyclopropenyl complexes is influenced by the nature of substituents on the three-membered ring and by the nature of ancillary ligand ar...

Abstract Terminal propargylic compounds containing an alkyne unit and an alcohol or ester group in the propargylic position have a fairly acidic acetylenic hydrogen atom; this makes them versatile substrates for further chemical transformation. Some transition metals such as ruthenium or copper exhibit specific affinity for terminal propargylic compounds, generating dielectrophilic ruthenium– o...

The effects of ruthenium red and the related compounds tetraamine palladium (4APd) and tetraamine platinum (4APt) were studied on the ryanodine activated Ca2+ release channel reconstituted in planar bilayers with the immunoaffinity purified ryanodine receptor. Ruthenium red, applied at submicromolar concentrations to the myoplasmic side (cis), induced an all-or-none flickery block of the ryanod...

A number of new ruthenium compounds have been synthesised, isolated and characterised, which exhibit excellent cytotoxicity against a number of different human tumour cell lines including a defined cisplatin resistant cell line and colon cancer cell lines. Addition of hydrophobic groups to the ruthenium molecules has a positive effect on the cytotoxicity values. Evidence is provided that, after...

Under physiologically relevant conditions, cis-bis(2,2'-bipyridine)dichlororuthenium(II), [cis-Ru(2,2'-bipy)2Cl2] was observed to bind to folic acid via replacement of the two chloride ligands. This binding was shown to be pH dependent and afforded diastereomers, the structures of which were determined by 1- and 2D NMR spectroscopic techniques. We propose that when studying the cytotoxicity of ...

Over the past few years, the organometalled compounds, including ruthenium, gained a lot of attention as anticancer agents. We report on the clioquinol-ruthenium complex [Ru(η6-p-cymene)(Cq)Cl] as a potent inhibitor of cathepsin B, a lysosomal cysteine peptidase, involved in tumour cell invasion and metastasis. In the low micromolar concentration range, the clioquinol-ruthenium complex did not ...

Trypanosoma lewisi bloodstream and culture forms were agglutinated differentially with low concentrations of the cationic compounds: ruthenium red, ruthenium violet, Alcian blue chloride, 1-hexadecylpyridinium chloride, lanthanum chloride, and cationized ferritin. The bloodstream form trypanosomes gave the highest agglutination levels with each of the compounds tested. Ruthenium red was the mos...

Ruthenium complexes are considered as potential replacements for platinum compounds in oncotherapy. Their clinical development is handicapped by a lack of consensus on their mode of action. In this study, we identify three histones (H3.1, H2A, H2B) as possible targets for an anticancer redox organoruthenium compound (RDC11). Using purified histones, we confirmed an interaction between the ruthe...